CohBar, Inc. (CWBR)
| Market Cap | 17.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.48M |
| Shares Out | 86.98M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 309,626 |
| Open | 0.202 |
| Previous Close | 0.205 |
| Day's Range | 0.198 - 0.210 |
| 52-Week Range | 0.180 - 2.270 |
| Beta | 2.55 |
| Analysts | Buy |
| Price Target | 2.93 (+1,376.1%) |
| Earnings Date | May 16, 2022 |
About CWBR
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CWBR stock is "Buy." The 12-month stock price forecast is 2.93, which is an increase of 1,376.07% from the latest price.
News
CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Conference call and webcast today at 5:00 p.m. ET, May 16, 2022 Conference call and webcast today at 5:00 p.m. ET, May 16, 2022
CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal
MENLO PARK, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded...
CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Conference call and webcast at 5:00 p.m. ET today, March 29, 2022 Conference call and webcast at 5:00 p.m. ET today, March 29, 2022
CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar to Present at H.C. Wainwright BIOCONNECT Conference
MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome ...
CohBar Announces Changes to its Board of Directors and R&D Leadership
Founding board members transition to reconstituted Scientific Advisory Board
CohBar's CEO to Participate in Upcoming BIO Webinar
MENLO PARK, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...
7 Penny Stocks With the Potential to 10X in 2022
The broader market looks expensive, but these penny stocks provide low-cost opportunities for considerable upside according to analysts. The post 7 Penny Stocks With the Potential to 10X in 2022 appeare...
CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update
Company to host conference call at 5:00 p.m. ET
5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes
There are so many traders looking for the best penny stocks 2021… The post 5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informati...
CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021
Company to host conference call at 5:00 p.m. ET Company to host conference call at 5:00 p.m. ET
CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
MENLO PARK, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic dise...
CohBar Announces Proposed Public Offering of Common Stock and Warrants
MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic dise...
CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021
MENLO PARK, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...
CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference
MENLO PARK, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...
CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors
MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...
CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH)
MENLO PARK, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...
CohBar Appoints Carol Nast to Its Board of Directors
MENLO PARK, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...
CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity
MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...
CohBar Stock Slumps As Data From NASH, Obesity Candidate Delayed By Almost Two Months
CohBar Inc (NASDAQ: CWBR) has updated the timing for releasing Phase 1a/1b trial data of CB4211 for the potential treatment of nonalcoholic steatohepatitis (NASH) and obesity. The process of data entry...
CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity
MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...
CohBar to Present at the BIO 2021 Digital Conference
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...